As of 2025-11-15, the EV/EBITDA ratio of Sorrento Therapeutics Inc (SRNE) is -0.23. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SRNE's latest enterprise value is 77.36 mil USD. SRNE's TTM EBITDA according to its financial statements is -340.66 mil USD. Dividing these 2 quantities gives us the above SRNE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 15.0x - 16.3x | 15.8x |
| Forward P/E multiples | 14.9x - 20.2x | 17.0x |
| Fair Price | (7.83) - (8.49) | (8.55) |
| Upside | -104549.8% - -113338.4% | -114162.3% |
| Date | EV/EBITDA |
| 2025-11-12 | -0.23 |
| 2025-11-11 | -0.23 |
| 2025-11-10 | -0.23 |
| 2025-11-07 | -0.23 |
| 2025-11-06 | -0.23 |
| 2025-11-05 | -0.23 |
| 2025-11-04 | -0.23 |
| 2025-11-03 | -0.23 |
| 2025-10-31 | -0.23 |
| 2025-10-30 | -0.23 |
| 2025-10-29 | -0.23 |
| 2025-10-28 | -0.23 |
| 2025-10-27 | -0.22 |
| 2025-10-24 | -0.22 |
| 2025-10-23 | -0.22 |
| 2025-10-22 | -0.22 |
| 2025-10-21 | -0.23 |
| 2025-10-20 | -0.23 |
| 2025-10-17 | -0.23 |
| 2025-10-16 | -0.23 |
| 2025-10-15 | -0.23 |
| 2025-10-14 | -0.22 |
| 2025-10-13 | -0.22 |
| 2025-10-10 | -0.22 |
| 2025-10-09 | -0.22 |
| 2025-10-08 | -0.22 |
| 2025-10-07 | -0.22 |
| 2025-10-06 | -0.22 |
| 2025-10-03 | -0.22 |
| 2025-10-02 | -0.22 |
| 2025-10-01 | -0.22 |
| 2025-09-30 | -0.22 |
| 2025-09-29 | -0.22 |
| 2025-09-26 | -0.22 |
| 2025-09-25 | -0.22 |
| 2025-09-24 | -0.22 |
| 2025-09-23 | -0.22 |
| 2025-09-22 | -0.22 |
| 2025-09-19 | -0.22 |
| 2025-09-18 | -0.22 |
| 2025-09-17 | -0.22 |
| 2025-09-16 | -0.22 |
| 2025-09-15 | -0.22 |
| 2025-09-12 | -0.22 |
| 2025-09-11 | -0.22 |
| 2025-09-10 | -0.22 |
| 2025-09-09 | -0.22 |
| 2025-09-08 | -0.22 |
| 2025-09-05 | -0.22 |
| 2025-09-04 | -0.22 |